3:51 PM
 | 
Jan 06, 2017
 |  BC Extra  |  Company News

Ionis, Novartis forge cardiovascular deal

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and its Akcea Therapeutics subsidiary granted Novartis AG (NYSE:NVS; SIX:NOVN) exclusive, worldwide options to develop and commercialize AKCEA-APO(a)-LRx (IONIS-APO(a)-LRx) and AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx), which are antisense therapies for cardiovascular disorders.

Ionis and Akcea are to receive an upfront option payment of $75 million and a $100...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >